Indeed, previous studies showed that CDK12 inhibition by dinaciclib, a pan‐CDK inhibitor, sensitised to PARPi triple negative breast cancer cells that are wild type for BRCA1/2 [179]. Here, CDK12 is linked to triple-negative breast carcinoma.